
The fund is rated 4.5 stars. The strongest areas were investment selection within each asset type, investment selection within each industry, and balance between returns and downside risk. Higher annual fee of 2.05% and above-average fund size of Rs 3,750.04 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing, a good risk-reward ratio. It is important to note, however, that this fund has a 3750.036 AUM and a 2.05 expense ratio. Considering all these factors, we have rated this fund as 4.5 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
13 Nov 2026 મુજબ
31 Oct 2026 મુજબ
31 Oct 2026 મુજબ
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| Apollo Hospitals Enterprise Ltd. | 7.89% | ₹293.96 Cr | 3,47,965 |
| Ipca Laboratories Ltd. | 7.49% | ₹279.12 Cr | 14,47,871 |
| Cipla Ltd. | 7.40% | ₹275.97 Cr | 20,01,379 |
| Sun Pharmaceutical Industries Ltd. | 7.32% | ₹272.98 Cr | 15,35,592 |
| Gland Pharma Ltd. | 6.61% | ₹246.21 Cr | 7,95,267 |
| Sai Life Sciences Ltd. | 6.17% | ₹229.79 Cr | 14,75,348 |
| Globus Medical Inc | 5.36% | ₹199.83 Cr | 2,68,800 |
| Alkem Laboratories Ltd. | 4.73% | ₹176.24 Cr | 3,44,654 |
| Divi's Laboratories Ltd. | 4.41% | ₹164.52 Cr | 1,68,223 |
| Cohance Lifesciences Ltd. | 3.82% | ₹142.31 Cr | 32,02,999 |
Long term capital growth. Investment in equity and equity related Securities of healthcare and pharmaceutical companies/entities.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.
Exit load of 0.50% if redeemed within 1 month.
મ્યુચ્યુઅલ ફંડ્સ બજાર જોખમને આધિન છે. તમામ યોજના દસ્તાવેજો ધ્યાનથી વાંચો.